Cognitive Decline

1
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
FINGER 2.0 multidomain lifestyle-based interventionPhase 21 trial
Active Trials
NCT05109169Recruiting600Est. Jun 2027
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Dalcroze Eurhythmics ProgramN/A1 trial
Active Trials
NCT03384602CompletedEst. Nov 2022
BioMarin Pharmaceutical
1 program
laronidaseN/A1 trial
Active Trials
NCT00852358Completed9Est. Apr 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Merck & Co.FINGER 2.0 multidomain lifestyle-based intervention
City TherapeuticsDalcroze Eurhythmics Program
BioMarin Pharmaceuticallaronidase

Clinical Trials (3)

Total enrollment: 609 patients across 3 trials

NCT05109169Merck & Co.FINGER 2.0 multidomain lifestyle-based intervention

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Start: Jan 2023Est. completion: Jun 2027600 patients
Phase 2Recruiting
NCT03384602City TherapeuticsDalcroze Eurhythmics Program

MOVE for Your MIND

Start: Dec 2017Est. completion: Nov 2022
N/ACompleted
NCT00852358BioMarin Pharmaceuticallaronidase

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Start: Jun 2009Est. completion: Apr 20159 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 609 patients
4 companies competing in this space